Who Owns Cytokinetics Stock?
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 125.87%
- Institutions (% of float)
- 126.69%
- Held by insiders
- 0.65%
- Institutional holders
- 658
- Institutions 99.4%
- Insiders 0.6%
- Public and other 0.0%
Who owns Cytokinetics stock?
Institutional investors own about 125.9% of Cytokinetics's shares, spread across 658 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.65% of CYTK.
The largest institutional holders are Blackrock Inc. (16.15%), T. Rowe Price Investment Management, Inc. (15.04%) and Wellington Management Group, LLP (5.57%). Together, the top 10 institutions control 67.1% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their CYTK positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CYTK
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 20.09M | 16.15% | +21.4% |
| T. Rowe Price Investment Management, Inc. | 18.72M | 15.04% | +6.8% |
| Wellington Management Group, LLP | 6.93M | 5.57% | -13.5% |
| Vanguard Portfolio Management LLC | 6.71M | 5.39% | +14.8% |
| State Street Corporation | 6.49M | 5.22% | +13.0% |
| Vanguard Capital Management LLC | 6.12M | 4.92% | +11.5% |
| FMR, LLC | 5.03M | 4.04% | -53.1% |
| Avoro Capital Advisors LLC | 5.00M | 4.02% | +50.0% |
| Bank of America Corporation | 4.64M | 3.73% | +48.3% |
| Geode Capital Management, LLC | 3.71M | 2.98% | +15.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CYTK
| Fund | Shares | % Held |
|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 6.29M | 5.05% |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 4.75M | 3.82% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.31M | 3.47% |
| iShares Trust-iShares Russell 2000 ETF | 3.37M | 2.71% |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.34M | 2.69% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.11M | 2.50% |
| SmallCap World Fund Inc | 3.00M | 2.41% |
| Fidelity Securities Fund-Fidelity OTC Portfolio | 2.21M | 1.78% |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1.97M | 1.58% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.79M | 1.44% |
Frequently asked questions
Who is the largest shareholder of Cytokinetics?
Blackrock Inc. is the largest institutional shareholder of CYTK, owning 16.15% of shares outstanding (20.09M shares) as of its latest 13F filing.
What percentage of Cytokinetics is owned by institutions?
Institutions own about 125.9% of CYTK shares and 126.7% of the public float.
How much of Cytokinetics do insiders own?
Insiders, such as officers and directors, own about 0.65% of CYTK shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.